Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 4, 2012, Pages 965-976

  Mamidipudi, Vidya ^a   Shi, Tao ^a   Brady, Helen ^a   Surapaneni, Sekhar ^a   Chopra, Rajesh ^a   Aukerman, Sharon L ^a   Heise, Carla ^a   Sung, Victoria ^a  

^a CELGENE CORPORATION   (United States)

Author keywords

Amrubicin; Anthracycline; Multi drug resistance; Topoisomerase II inhibitor

Indexed keywords

AMRUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GLYCOPROTEIN P;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CANCER RESISTANCE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CROSS RESISTANCE; DNA DAMAGE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IMAGING; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; M PHASE CELL CYCLE CHECKPOINT; MULTIDRUG RESISTANCE; OVARY CANCER; PRIORITY JOURNAL;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CASPASE 3; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA DAMAGE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; OVARIAN NEOPLASMS; TOPOISOMERASE II INHIBITORS; UTERINE NEOPLASMS;

EID: 84859792029     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1782-x     Document Type: Article

References (41)

1. Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57:727-741
2. Yamamoto M, Takakura A, Masuda N (2009) Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin. Drug Des Dev Ther 2:189-192
3. Morisada S, Yanagi Y, Noguchi T, Kashiwazaki Y, Fukui M (1989) Antitumor activities of a novel 9-aminoanthracycline (SM-5887) against mouse experimental tumors and human tumor xenografts. Jpn J Cancer Res 80:69-76 (Pubitemid 20027201)
4. Suzuki T, Minamide S, Iwasaki T, Yamamoto H, Kanda H (1997) Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: comparative study with doxorubicin. Invest New Drugs 15:219-225 (Pubitemid 27453876)
5. Ogawa M (1999) Novel anticancer drugs in Japan. J Cancer Res Clin Oncol 125:134-140
6. Noda T, Watanabe T, Kohda A, Hosokawa S, Suzuki T (1998) Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16:121-128 (Pubitemid 28495213)
7. Galustian C, Sung V, Bartlett B, Rolfe L, Dalgleish A (2010) Recent pharmacological advances: focus on small-cell lung cancer. Clin Med Insights Ther 2:643-653
8. Noguchi T, Ichii S, Morisada S, Yamaoka T, Yanagi Y (1998) Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin. Jpn J Cancer Res 89:1061-1066 (Pubitemid 28544783)
9. Ettinger DS, Jotte R, Lorigan P et al (2010) Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 28:2598-2603
10. Jotte R, Conkling P, Reynolds C, et al (2009) Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy [abstract]. J Clin Oncol 27(Suppl):Abstract 8028
11. Inoue A, Sugawara S, Yamazaki K et al (2008) Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan lung cancer study group trial 0402. J Clin Oncol 26:5401-5406
12. Dal Ben D, Palumbo M, Zagotto G, Capranico G, Moro S (2007) DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation. Curr Pharm Des 13:2766-2780 (Pubitemid 350130973)
13. Simůnek T, Stérba M, Popelová O, Adamcová M, Hrdina R, Gersl V (2009) Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 61:154-171
14. Hanada M, Mizuno S, Fukushima A, Saito Y, Noguchi T, Yamaoka T (1998) A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89:1229-1238 (Pubitemid 29008005)
15. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1998) Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067-1073 (Pubitemid 28544784)
16. Litman T, Skovsgaard T, Stein WD (2003) Pumping of drugs by P-glycoprotein: a two-step process? J Pharmacol Exp Ther 307:846-853 (Pubitemid 37494200)
17. Nielsen D, Maare C, Skovsgaard T (1996) Cellular resistance to anthracyclines. Gen Pharmacol 27:251-255 (Pubitemid 26129184)
18. Mirski SE, Gerlach JH, Cole SP (1987) Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47:2594-2598 (Pubitemid 17083146)
19. Harker WG, Sikic BI (1985) Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45:4091-4096 (Pubitemid 16224856)
20. Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y (2010) Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 46:1692-1702
21. Weinstein JN (2006) Spotlight on molecular profiling: "integromic"analysis of the NCI-60 cancer cell lines. Mol Cancer Ther 5:2601-2605
22. Liscovitch M, Ravid D (2007) A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADRRES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 245:350-352 (Pubitemid 44959366)
23. Slovak ML, Ho JP, Bhardwaj G, Kurz EU, Deeley RG, Cole SP (1993) Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res 53:3221-3225 (Pubitemid 23223284)
24. The R Project for Statistical Computing (2011) R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. http://www.R-project.org. Accessed 18 February 2011
25. Smyth GK (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:Article 3
26. Huang X, Darzynkiewicz Z (2006) Cytometric assessment of histone H2AX phosphorylation: a reporter of DNA damage. Methods Mol Biol 314:73-80
27. Beck WT (1990) Strategies to circumvent multidrug resistance due to P-glycoprotein or to altered DNA topoisomerase II. Bull Cancer 77:1131-1141
28. Sirotnak FM, Jacobsen DM, Yang CH (1986) Alteration of folate analogue transport following induced maturation of HL-60 leukemia cells. Early decline in mediated influx, relationship to commitment, and functional dissociation of entry and exit routes. J Biol Chem 261:11150-11155 (Pubitemid 17216717)
29. Hammond JR, Johnstone RM, Gros P (1989) Enhanced efflux of [3H]vinblastine from Chinese hamster ovary cells transfected with a full-length complementary DNA clone for the MDR1 gene. Cancer Res 49:3867-3871 (Pubitemid 19197413)
30. Traunecker HC, Stevens MC, Kerr DJ, Ferry DR (1999) The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells. Br J Cancer 81:942-951 (Pubitemid 29516136)
31. Morjani H, Millot JM, Belhoussine R, Sebille S, Manfait M (1997) Anthracycline subcellular distribution in human leukemic cells by microspectrofluorometry: factors contributing to drug-induced cell death and reversal of multidrug resistance. Leukemia 11:1170-1179 (Pubitemid 27345973)
32. Yamaoka T, Hanada M, Ichii S, Morisada S, Noguchi T, Yanagi Y (1999) Uptake and intracellular distribution of amrubicin, a novel 9-amino- anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells. Jpn J Cancer Res 90:685-690 (Pubitemid 29332929)
33. Horio Y, Osada H, Shimizu J, Ogawa S, Hida T, Sekido Y (2010) Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines. Cancer Chemother Pharmacol 66:237-243
34. Christmann M, Tomicic MT, Roos WP, Kaina B (2003) Mechanisms of human DNA repair: an update. Toxicology 193:3-34 (Pubitemid 37340141)
35. Deriano L, Guipaud O, Merle-Béral H et al (2005) Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 105:4776-4783 (Pubitemid 40807303)
36. Corn PG, El-Deiry WS (2007) Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol Ther 6:1858-1866 (Pubitemid 351590397)
37. Medema RH, Klompmaker R, Smits VA, Rijksen G (1998) p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 16:431-441 (Pubitemid 28062070)
38. Boulton SJ (2009) DNA repair: a heavyweight joins the fray. Nature 462:857-858
39. Ashley N, Poulton J (2009) Anticancer DNA intercalators cause p53-dependent mitochondrial DNA nucleoid re-modelling. Oncogene 28:3880-3891
40. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461:1071-1078
41. Ravi D, Muniyappa H, Das KC (2005) Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. J Biol Chem 280:40084-40096 (Pubitemid 41779143)